Skip to main content

Melanoma Clinical Trials

Review the melanoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 248

A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: University of Colorado, Denver, Colorado
Propranolol Hydrochloride and Pembrolizumab in Treating Patients with Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Status: Temporarily Closed to Accrual
Location: 4 locations
Quisinostat for Preventing Metastasis after Treatment of High-Risk Uveal Melanoma
Status: Temporarily Closed to Accrual
Location: 8 locations
Azacitidine and Pembrolizumab in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations
KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
The Impact of an Antibiotic (Cefazolin) before Surgery on the Microbiome in Patients with Stage I-II Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
DNX-2440 for Resectable Colorectal Liver Metastasis
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Temporarily Closed to Accrual and Intervention
Location: See ClinicalTrials.gov
Comparing Single vs Multiple Doses of Radiation for Patients on Immunotherapy for Breast, Kidney, Small Cell Lung Cancer, Non-Small Cell Lung Cancer or Melanoma that Has Spread to the Brain, HYPOGRYPHE Study
Status: Active
Location: 35 locations
Integrative Medicine for the Improvement of Patient-Reported Outcomes, Values, and Experience
Status: Active
Location: 7 locations
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
Status: Active
Location: 3 locations
A Prebiotic Food-Enriched Dietary Intervention Added to Standard Immune Checkpoint Blockade Therapy for Improving Immune Response in Patients with Resectable Stage IIIB-D or Stage IV Cutaneous Melanoma or Locally Advanced Mucosal Melanoma, NEO-PreFED Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients with Melanoma or Genitourinary Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients with Metastatic Melanoma and Metastatic Kidney Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Dietary Interventions to Improve Gut Microbiome in Patients with Stage IIB-IIIC Melanoma and Stage IB-IIIC Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors, CANS Trial
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Continuous Monitoring of Vital Signs and Laboratory Values to Reduce Side Effects in Cancer Patients Receiving Chemotherapy with Moderate or High Risk of Febrile Neutropenia or Immunotherapy, PR-DOC Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Prebiotic Food-Enriched Diet to Enhance the Microbiome and Response to First-Line Immunotherapy in Patients with Stage III or IV Unresectable Cutaneous, Uveal, Acral or Mucosal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas